Heron Therapeutics (HRTX) - Quarterly EPS earnings growth

Official company branding of Heron (HRTX)

Heron Therapeutics (HRTX) is implementing software robots to process clinic results. The recorded quarterly EPS dynamics demonstrate current trends, where the 74.20 level represents the current value. The brand is renowned for developing treatments to combat oncology and acute pain, reducing opioid dependence. A reliable temperature-controlled supply chain ensures the high-quality delivery of medications to medical centers.

Heron Therapeutics, Inc. (HRTX) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/18/2026

Analytical breakdowns for Heron Therapeutics

- market value and analyst target forecast:
Fundamental company analysis:Heron, HRTX
Manufactured product of Heron Therapeutics

Logistics optimization and production outsourcing provide Heron Therapeutics (HRTX) with high operational flexibility. These factors directly impact the quarterly growth of net income per share. This metric is based on the continuous recalculation of fresh reporting data, revealing EPS dynamics. The stability of this chart often masks the risk of a sharp breakout of quotes beyond the range boundaries. Analyzing these fluctuations allows for an objective adjustment of the assets' fair value.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc